Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry

Edward  W Zhou; Matthew  J Jackson; Fred Ledley

doi:2689-0186

Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry

Edward W Zhou
, Matthew J Jackson
, Fred Ledley

Natural and Applied Sciences

Research output: Contribution to journal › Article

Abstract

The launch of the Advanced Research Projects Agency for Health to advance new cures and address public concern regarding drug prices has raised questions about the roles of government and industry in drug development.

Original language	English
Pages (from-to)	e231921
Journal	Unknown journal
Volume	4
Issue number	7
DOIs	https://doi.org/2689-0186
State	Published - 2023

Access to Document

2689-0186

Cite this

@article{c148270f977a4cd6b9c4becafcda140f,

title = "Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry",

abstract = "The launch of the Advanced Research Projects Agency for Health to advance new cures and address public concern regarding drug prices has raised questions about the roles of government and industry in drug development.",

author = "Zhou, \{Edward W\} and Jackson, \{Matthew J\} and Fred Ledley",

year = "2023",

doi = "2689-0186",

language = "English",

volume = "4",

pages = "e231921",

journal = "Unknown journal",

number = "7",

}

TY - JOUR

T1 - Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry

AU - Zhou, Edward W

AU - Jackson, Matthew J

AU - Ledley, Fred

PY - 2023

Y1 - 2023

N2 - The launch of the Advanced Research Projects Agency for Health to advance new cures and address public concern regarding drug prices has raised questions about the roles of government and industry in drug development.

AB - The launch of the Advanced Research Projects Agency for Health to advance new cures and address public concern regarding drug prices has raised questions about the roles of government and industry in drug development.

U2 - 2689-0186

DO - 2689-0186

M3 - Article

VL - 4

SP - e231921

JO - Unknown journal

JF - Unknown journal

IS - 7

ER -

Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry

Abstract

Access to Document

Fingerprint

Cite this